In this research, we found that ESZWD process the ability to treat CHF-HKYd by reducing the levels of NT-proBNP, Ang II, ALD, ROS, and MDA in serum, and increasing the content of SOD, while having no effects on TNF-α and IL-6. The gene discussed is AGT; the disease is congestive heart failure.